Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Chronic hyperglycemia downregulates GLP-1 receptor signaling in pancreatic -cells via protein kinase A
Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, currently under clinical investigation and not yet approved by the MHRA or EMA
Anti-oxidation: removes hydroxyl free radicals and protects DNA from oxidative damage
CPT Pharmacometrics Syst Pharmacol
It has been extensively studied for its role in melanogenesis and various physiological processes
Hepatic and Metabolic Benefits A MAFLD/MASLD (metabolic dysfunction-associated steatotic liver disease) sub-study of the Phase 2 obesity trial reported that over 85% of participants on the highest retatrutide doses achieved more than 30% reduction in liver fat content measured by MRI, with many reaching complete resolution of steatosis
US$ 28.63
US$ 21.42
US$ 23.60
US$ 29.28
US$ 26.91
US$ 20.35
